301 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28274635	381	Identification of novel TACE inhibitors compatible with topical application.	Nestl�
27966948	86	Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.	Pharmaceutical
28337319	28	Bifunctional Inhibitors as a New Tool To Reduce Cancer Cell Invasion by Impairing MMP-9 Homodimerization.	Universit£
27914947	11	Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs).	University of Florence
27825552	152	Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.	Takeda Pharmaceutical
27452283	241	Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.	Jadavpur University
27038494	18	Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.	Fudan University
26871660	68	Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.	San Raffaele Scientific Institute
26653735	81	Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.	Pfizer
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
26638045	58	Synthesis, experimental evaluation and molecular modelling of hydroxamate derivatives as zinc metalloproteinase inhibitors.	Uit The Arctic University of Norway
26346367	77	Sulfonamide derivatives containing dihydropyrazole moieties selectively and potently inhibit MMP-2/MMP-9: Design, synthesis, inhibitory activity and 3D-QSAR analysis.	Nanjing University
26386821	15	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase.	Shandong University
26263024	47	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.	Universit£
26192023	71	SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.	Florida Atlantic University
25264600	64	Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.	Takeda Pharmaceutical
25921268	36	New matrix metalloproteinase inhibitors based on¿-fluorinateda-aminocarboxylic anda-aminohydroxamic acids.	Westf£Lische Wilhelms-Universit£T M£Nster
25438884	11	A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.	University Medical Center Groningen
25265401	38	Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.	Universidad Ceu San Pablo
25192810	66	Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.	Takeda Pharmaceutical
24028490	46	O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.	University of Notre Dame
23375794	220	Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.	Nanjing University of Chinese Medicine
23353736	41	Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).	Second Military Medical University
23287054	46	Sulphonamides: Deserving class as MMP inhibitors?	Indian Institute of Technology (Bhu)
23458498	24	Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.	Universit£
23246356	52	MMP inhibition by barbiturate homodimers.	Trinity College
17275314	701	Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.	Pomona College
21669521	44	Selective non zinc binding inhibitors of MMP13.	Astrazeneca
23134659	74	Design and synthesis of procollagen C-proteinase inhibitors.	Fibrogen
21413808	170	Synopsis of some recent tactical application of bioisosteres in drug design.	Bristol-Myers Squibb Pharmaceutical Research and Development
21780776	40	Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.	Wroclaw University of Technology
21413800	56	A one-pot synthesis and biological activity of ageladine A and analogues.	Macquarie University
23149299	50	Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.	Universit£
22540974	67	A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation.	University Hospital M£Nster
22248361	24	Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.	Trinity College
22737278	44	Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.	TBA
22658537	76	Natural products as a gold mine for selective matrix metalloproteinases inhibitors.	East China University of Science and Technology
22175799	22	Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.	Alantos Pharmaceuticals
24900330	47	The impact of ionization States of matrix metalloproteinase inhibitors on docking-based inhibitor design.	TBA
22342144	72	Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.	Panthera Biopharma
19715320	87	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.	University of Florida
19635666	119	Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.	Incyte
19128977	4	Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloproteinases.	Uned
19095454	63	Current perspective of TACE inhibitors: a review.	The M. S. University of Baroda
17981034	51	1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.	Johnson & Johnson Pharmaceutical Research and Development
17980583	46	Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).	Johnson & Johnson Pharmaceutical Research and Development
18086526	85	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.	Johnson & Johnson Pharmaceutical Research and Development
18257543	16	Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.	The Hebrew University of Jerusalem
18251495	69	Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
18061445	103	Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).	Bristol-Myers Squibb Research and Development
18029173	316	Synthesis and evaluation of novel heterocyclic MMP inhibitors.	North Dakota State University
17956082	86	Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET.	University Hospital of The Westf£Lische Wilhelms-Universit£T M£Nster
17127067	21	Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs.	Instituto Superior T£Cnico
17276072	95	Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates.	Universit£
15857146	30	C-5-disubstituted barbiturates as potential molecular probes for noninvasive matrix metalloproteinase imaging.	University Hospital of The Westf£Lische Wilhelms-Universit£T
15713379	40	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.	Universit£
15582436	7	N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.	Sejong University
15214773	76	Fragment-based drug discovery.	Sunesis Pharmaceuticals
15139760	110	Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.	The Hebrew University of Jerusalem
12930146	170	Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.	Institut De Recherches Servier
12773042	195	Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
12773041	119	Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.	Wyeth Research
11831904	172	New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.	Nippon Organon K.K.
11472217	157	Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.	Dupont Pharmaceuticals
11472202	143	Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.	TBA
10669559	180	Protease inhibitors: current status and future prospects.	University of Queensland
10649971	180	Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.	Parke-Davis Pharmaceutical Research
10579818	162	Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
9888835	42	Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.	Procter and Gamble Pharmaceuticals
9733482	31	Discovery of potent, achiral matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
14980648	16	New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.	Universit£
15177439	96	Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.	Pfizer
11327577	86	Heterocycle-based MMP inhibitors with P2' substituents.	Procter and Gamble Pharmaceuticals
11677139	92	The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.	Wyeth-Ayerst Research
11206468	24	Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.	Wyeth-Ayerst Research
11206467	44	The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.	Wyeth-Ayerst Research
11514167	88	The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.	Wyeth-Ayerst Research
11378378	34	Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.	Celltech-Chiroscience
10340614	20	Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.	Dupont Pharmaceuticals
10450979	4	Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.	University of Cambridge
10397503	40	Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.	Universit£
9873598	39	The synthesis and biological activity of a novel series of diazepine MMP inhibitors.	Wyeth-Ayerst Research
22386984	67	In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.	Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
22175825	19	Potent inhibitors of LpxC for the treatment of Gram-negative infections.	Pfizer
22118188	50	A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography.	University Hospital M£Nster
22153941	140	Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.	Astrazeneca
22017539	75	Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.	Boehringer Ingelheim Pharmaceuticals
22017477	35	Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.	Instituto Superior T£Cnico
22153340	37	Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD).	Pfizer
22082667	67	Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.	Microbiotix
21851064	3	Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis.	Indiana University School of Medicine
21925881	60	Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.	Johnson & Johnson Pharmaceutical Research & Development
21548582	57	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.	University of Illinois At Chicago
21866961	28	Selective water-soluble gelatinase inhibitor prodrugs.	University of Notre Dame
21764590	98	N-substituted homopiperazine barbiturates as gelatinase inhibitors.	Trinity College
20726512	282	Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.	Pfizer
21514700	56	Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.	Universit£
21536437	219	Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.	Astrazeneca
20638281	56	Structure and activity relationships of tartrate-based TACE inhibitors.	Merck Research Laboratories
21507637	102	MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.	Pfizer
21493063	67	MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.	Pfizer
21458257	87	2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.	Merck Research Laboratories
21417219	179	Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.	Central Pharmaceutical Research Institute
24900296	38	Sulfonate-Containing Thiiranes as Selective Gelatinase Inhibitors	TBA
21078557	34	Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.	Yonsei University
21106451	39	Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.	Merck Research Laboratories
20529685	70	MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.	Pfizer
20529684	112	Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.	Pfizer
20180536	128	Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.	Universit£
20172725	49	Discovery and SAR of hydantoin TACE inhibitors.	Merck Research Laboratories
20053563	10	Identification of potential and selective collagenase, gelatinase inhibitors from Crataegus pinnatifida.	Wonkwang University Sanbon Medical Center
20005097	58	Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.	Pfizer
19703773	63	The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.	Gsk Medicines Research Centre
19775099	184	Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.	Universit£
19625186	59	3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding.	Wyeth Research
19725580	93	Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.	Wyeth Research
19606871	124	N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.	Universit£
	2	Synthesis of conformationally constrained potential inhibitors of mammalian metalloproteinases	TBA
	39	Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety	TBA
	97	Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocket	TBA
	30	Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics	TBA
	17	Design and synthesis of the cartilage protective agent (CPA, Ro32-3555)	TBA
	44	Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistry	TBA
	47	Hydroxamate inhibitors of human gelatinase B (92 kDa)	TBA
	5	Inhibition of metalloproteinase by futoenone derivatives	TBA
19457660	90	Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.	Incyte
19053764	101	Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.	Instituto Superior TéCnico
18945617	50	Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.	Pfizer
18790648	317	Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.	University of Athens
18782669	90	Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.	Université
18442906	40	Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.	North Dakota State University
18364257	16	Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study.	The Scripps Research Institute
17719700	39	Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.	Università
17623656	34	Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.	Pfizer
18083558	112	beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.	Johnson & Johnson Pharmaceutical Research and Development
18068976	132	Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.	Incyte
18036818	157	Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.	Incyte
18029177	57	A novel series of highly selective inhibitors of MMP-3.	Pfizer
17936631	25	Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.	Yonsei University
17591762	102	Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.	Pfizer
17583333	4	Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.	Università
17512742	32	Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.	Université
17368021	55	Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17276676	112	A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
17256836	84	Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.	Incyte
17188863	107	Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
17088065	106	alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.	Università
17064892	123	Identification of potent and selective TACE inhibitors via the S1 pocket.	Wyeth Research
17027261	153	Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
16723229	108	Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.	Wyeth Research
16632358	68	Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.	Johnson & Johnson Pharmaceutical Research and Development
16516466	175	Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16473009	23	Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16420030	38	Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.	Chinese Academy of Sciences
16392792	29	Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.	Aventis Pharma Deutschland
16289878	35	Conversion of potent MMP inhibitors into selective TACE inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
16107143	33	A combination of docking, QM/MM methods, and MD simulation for binding affinity estimation of metalloprotein ligands.	North Dakota State University
16084720	83	Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.	Wyeth Research
16002291	24	Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.	Pfizer
15953722	56	Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.	Pfizer
15908214	95	Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.	Bristol-Myers Squibb Pharmaceutical Research Institute
15837315	13	A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.	Università
15686921	55	Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).	Pharmaceutical Research Institute
15566296	142	Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.	Wyeth Research
15357971	228	Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
15341955	52	Synthesis and evaluation of novel oxazoline MMP inhibitors.	North Dakota State University
15324896	71	3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.	Pfizer
15125955	84	Reverse hydroxamate-based selective TACE inhibitors.	Kaken Pharmaceutical
15055993	30	Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.	Hokkaido Collaboration Center N-21
15006405	20	Synthesis and biological activity of selective azasugar-based TACE inhibitors.	Organon K.K.
14711305	26	Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.	University of Athens
14684295	109	Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.	Chinese Academy of Sciences
14643313	132	Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.	Bristol-Myers Squibb Pharmaceutical Research Institute
14643312	39	Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.	Bristol-Myers Squibb Pharmaceutical Research Institute
12877590	28	A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.	Pfizer
12877587	6	Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty.	National Cardiovascular Center Research Institute
12873518	81	Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.	Wyeth Research
12873505	20	Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12873504	36	Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.	Hokkaido Collaboration Center
12798337	6	Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.	Indiana University School of Medicine
12781190	113	Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Bristol-Myers Squibb Pharmaceutical Research Institute
12781187	15	Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Organon K.K.
12723945	167	Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.	Bristol-Myers Squibb Pharmaceutical Research Institute
12668018	138	Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.	Wyeth-Ayerst Research
12657268	13	Potent and selective aggrecanase inhibitors containing cyclic P1 substituents.	Bristol-Myers Squibb Pharmaceutical Research Institute
12408705	73	Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.	Bristol-Myers Squibb
12270165	80	Benzodiazepine inhibitors of the MMPs and TACE.	Wyeth Research
11958997	53	Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.	University of Bielefeld
11934588	69	Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.	Wyeth-Ayerst Research
11934587	19	Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.	Wyeth-Ayerst Research
11844676	48	Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.	Organon K.K.
11831905	33	New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.	Organon K.K.
11754593	148	Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.	Abbott Laboratories
11738583	45	Potent P1' biphenylmethyl substituted aggrecanase inhibitors.	Bristol-Myers Squibb Pharma
11708926	84	Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).	Glaxosmithkline
11585440	76	Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.	Dupont Pharmaceuticals
11585439	44	Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.	Dupont Pharmaceuticals
11563922	147	Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.	UniversitäT Bielefeld
11543676	45	Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.	Université
11543675	104	N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.	Université
11514157	48	N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.	Glaxosmithkline
11412980	48	Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.	Abbott Laboratories
11354379	37	Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.	Pfizer
11327602	58	Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.	Roche Research Center
32150407	27	Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.	Qpex Biopharma
31874775	176	Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors.	"A. Moro" University of Bari
11229774	40	Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).	Pfizer
11229773	73	Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.	Pfizer
11212095	65	General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.	Institut De Recherches Servier
32379447	44	Validating the 1,2-Difluoro Motif As a Hybrid Bioisostere of CF	Westf£Lische Wilhelms-Universit£T M£Nster
27563406	128	Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.	Roche Pharma Research and Early Development
10882354	19	Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.	Pfizer
27194201	164	Use of Osmotic Pumps to Establish the Pharmacokinetic-Pharmacodynamic Relationship and Define Desirable Human Performance Characteristics for Aggrecanase Inhibitors.	Eli Lilly
10794702	340	Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.	Università
30688452	94	Synthesis and Structural/Functional Characterization of Selective M14 Metallocarboxypeptidase Inhibitors Based on Phosphinic Pseudopeptide Scaffold: Implications on the Design of Specific Optical Probes.	Universitat Aut£Noma De Barcelona
10669564	189	Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.	Procter and Gamble Pharmaceuticals
31415980	68	Design, synthesis and preliminary bioactivity evaluations of 8-hydroxyquinoline derivatives as matrix metalloproteinase (MMP) inhibitors.	Shandong University
31251594	57	Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.	Monash University
10560745	46	Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.	Smithkline Beecham Pharmaceuticals
10411481	144	Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.	Cea
30954331	54	Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: Synthesis, antibacterial properties, and docking studies.	University of Hamburg
30926311	16	Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds.	University of Florence
10360755	17	P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.	Dupont Pharmaceuticals
10346925	40	Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.	Shionogi
10212120	34	Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.	Affymax Research Institute
30537832	7	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.	Monash University
30522899	28	Design, synthesis and biological evaluation of bifunctional inhibitors of membrane type 1 matrix metalloproteinase (MT1-MMP).	Universit£
29400967	136	Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.	Bristol-Myers Squibb
9871728	27	The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.	Wyeth-Ayerst Research
9871727	58	Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.	Affymax Research Institute
9871551	48	Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.	Dupont Pharmaceuticals
9632351	36	Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.	Affymax Research Institute
9599226	25	Macrocyclic amino carboxylates as selective MMP-8 inhibitors.	Dupont Pharmaceuticals
9599225	9	Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.	Dupont Pharmaceuticals
9548812	67	Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.	Kanebo
9484512	130	Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.	Shionogi
9457244	189	Matrix metalloproteinase inhibitors: a structure-activity study.	Glycomed
9191969	31	Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.	Institut De Recherche Servier
30846252	23	Recent developments in the synthesis and applications of phosphinic peptide analogs.	Wroclaw University of Technology
26810711	30	Fluorinated matrix metalloproteinases inhibitors--Phosphonate based potential probes for positron emission tomography.	Westf£Lische Wilhelms-Universit£T
8277511	57	Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.	Merck Research Laboratories
8126708	113	Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.	Glaxo Inc. Research Institute
23899323	87	Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.	University Hospital M£Nster
23688254	31	Design, synthesis, and initial evaluation of a high affinity positron emission tomography probe for imaging matrix metalloproteinases 2 and 9.	Eth Zurich
20056543	2	Anti-invasive and anti-angiogenic activities of naturally occurring dibenzodiazepine BU-4664L and its derivatives.	Toyama Prefectural University
17027271	13	Natural inhibitors targeting osteoclast-mediated bone resorption.	Chinese Academy of Sciences
30429099	25	Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates.	University of Pisa
30093347	10	Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity.	Weifang Medical University
30212201	17	Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing.	University of Notre Dame
29921475	37	Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration.	Guangxi Normal University
28756264	93	Discovery of dehydroabietic acid sulfonamide based derivatives as selective matrix metalloproteinases inactivators that inhibit cell migration and proliferation.	Southeast University
29727184	56	Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies.	Universit£
28818461	67	Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis.	Nestl�
30249495	241	Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.	Graz University of Technology
30034605	15	In Search of Selectivity in Inhibition of ADAM10.	University of Notre Dame
29028530	48	A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line.	Jadavpur University
28493718	2	Tamarixetin 3-O-?-d-Glucopyranoside from Azadirachta indica Leaves: Gastroprotective Role through Inhibition of Matrix Metalloproteinase-9 Activity in Mice.	National Institute of Pharmaceutical Education and Research
28850227	85	Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.	St. John'S University
28558971	38	Fused bi-heteroaryl substituted hydantoin compounds as TACE inhibitors.	Merck
28408220	55	First insight into structure-activity relationships of selective meprin? inhibitors.	Fraunhofer Institute For Cell Therapy and Immunology Izi
28653849	67	Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.	Scripps Florida
22299577	12	Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII.	Universit?? Di Firenze
21524149	13	Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.	Suven Life Sciences
16206837	9	Tyrosinase inhibition: conformational analysis based studies on molecular dynamics calculations of bipiperidine based inhibitors.	University of Karachi
9463476	21	DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.	Suntory Institute For Bioorganic Research
8524985	69	D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs.	Case Western Reserve University
7965765	14	Cloning and pharmacologic characterization of a thromboxane A2 receptor from K562 (human chronic myelogenous leukemia) cells.	University of Cincinnati
7680751	48	Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.	National Institute of Neurological Disorders and Stroke
7515823	54	Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family.	Novo Nordisk
7509389	8	Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	Fujisawa Pharmaceutical
19695884	156	Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.	Vernalis (R&D)
17034127	45	Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.	University of Newcastle Upon Tyne
19345579	14	Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.	Wyeth Research
19267461	53	Novel tricyclic inhibitors of IkappaB kinase.	Bristol-Myers Squibb